about
In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophreniaDevelopmental vulnerability of synapses and circuits associated with neuropsychiatric disorders.A Neurophysiological Perspective on a Preventive Treatment against Schizophrenia Using Transcranial Electric Stimulation of the Corticothalamic PathwayBLOC-1 deficiency causes alterations in amino acid profile and in phospholipid and adenosine metabolism in the postnatal mouse hippocampus.The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment.Glutamate carboxypeptidase II inhibition behaviorally and physiologically improves pyridoxine-induced neuropathy in rats.Abnormal partitioning of hexokinase 1 suggests disruption of a glutamate transport protein complex in schizophreniaATP-binding Cassette Subfamily C Member 5 (ABCC5) Functions as an Efflux Transporter of Glutamate Conjugates and Analogs.A systematic review of the effects of NMDA receptor antagonists on oscillatory activity recorded in vivo.Reduced sleep spindle activity point to a TRN-MD thalamus-PFC circuit dysfunction in schizophrenia.Mutant disrupted-in-schizophrenia 1 in astrocytes: focus on glutamate metabolismVesicular uptake of N-acetylaspartylglutamate is catalysed by sialin (SLC17A5).Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.Anti-NMDAR encephalitis: a new, severe and challenging enduring entity.The Role of Serine Racemase in the Pathophysiology of Brain Disorders.
P2860
Q28083121-9EEAE50F-5226-4A84-9281-210C927C886BQ30435763-12EC239E-5E6B-4F87-9B02-5530DD2526AFQ33607904-4DAC8EC7-808E-425D-809F-98CD2DD02CE7Q33899339-BC8C4552-5A59-4B4A-8B76-94A360515557Q33920257-4807852E-1B27-49C8-BA73-D0FC0D8EC1B2Q34256889-00757F8A-514F-4E13-BFF5-0551A105CDE1Q34406087-3D76350D-FA32-48C4-967E-764EA1F126F9Q36381928-2C4D29C9-C865-4E85-8BF0-63819C9C21A1Q38122300-8C1643CF-0760-43A6-A3C1-134EC241858CQ38857316-1581BA75-ADC2-482C-9C4E-A4BBF48B06E4Q41930161-55522644-526C-453F-B65F-0034C7858827Q44954480-7985EEF6-44CF-4C0E-85F1-819F916E1F7BQ47330693-55A736E9-24C2-405D-938B-59A423C0A311Q48205459-0101E111-09CA-470A-B096-307CFC0075D3Q50138246-5260BC03-E0EC-4C7D-8637-4DAF18E7AC24
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
NAAG, NMDA receptor and psychosis
@en
NAAG, NMDA receptor and psychosis.
@nl
type
label
NAAG, NMDA receptor and psychosis
@en
NAAG, NMDA receptor and psychosis.
@nl
prefLabel
NAAG, NMDA receptor and psychosis
@en
NAAG, NMDA receptor and psychosis.
@nl
P2860
P1476
NAAG, NMDA receptor and psychosis
@en
P2093
Joseph T Coyle
Richard Bergeron
P2860
P304
P356
10.2174/092986712799462685
P577
2012-01-01T00:00:00Z